Clario, the life sciences endpoint data solutions provider, has secured $6.0M in a Seed funding round. The company, a part of Thermo Fisher Scientific, offers comprehensive evidence generation solutions that combine eCOA, cardiac safety, medical imaging, precision motion, and respiratory endpoints.
With a history spanning over 50 years, Clario has supported more than 30,000 clinical trial opportunities across over 100 countries. Its solutions have been instrumental in over 70% of all FDA drug approvals since 2015, leveraging deep scientific expertise and broad endpoint technologies.














